Dividend, Quarterly Report, Recognition, Study Results, and New Drug Application – Research Report on Pfizer, Lilly, Regeneron, Vertex, and GSK
NEW YORK, Nov. 1, 2013 /PRNewswire/ — Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts’ Corner announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), and GlaxoSmithKline plc (NYSE: GSK). Today’s readers may access these reports free of charge – including full price targets, industry analysis and analyst ratings – via the links below.
Pfizer Inc. Research Report
On October 24, 2013, Pfizer Inc. (Pfizer) announced that its Board of Directors has declared a Q4 2013 dividend of $0.24 per common share. Pfizer reported that the dividend is payable on December 3, 2013, to shareholders of record at the close of business on November 8, 2013. The Full Research Report on Pfizer Inc. – including full detailed breakdown, analyst ratings and price targets – is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/d702_PFE]
Eli Lilly and Company Research Report
On October 23, 2013, Eli Lilly and Company (Lilly) released its Q3 2013 results. Lilly registered total revenue of $5.8 billion, 6.0% YoY in Q3 2013. The Company posted net income of $1.2 billion in Q3 2013, down compared to net income of $1.3 billion in Q3 2012. Lilly reported diluted EPS of $1.11 in Q3 2013, compared to diluted EPS of $1.18 in Q3 2012. Commenting on the results, John C. Lechleiter, Ph.D., Chairman, President, and CEO of Lilly, said, “As we navigate through a period of expiring patents for some of our largest products, Lilly continues to deliver solid financial results and to advance our late-stage pipeline, with four regulatory filings completed this year alone.” Lechleiter continued, “We are successfully executing our strategy which will enable us to return to growth after 2014 by bringing to the market new medicines that make a real difference for patients.” The Full Research Report on Eli Lilly and Company – including full detailed breakdown, analyst ratings and price targets – is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/977d_LLY]
Regeneron Pharmaceuticals, Inc. Research Report
On October 24, 2013, Regeneron Pharmaceuticals, Inc. (Regeneron) announced that it has been ranked by Science magazine as the #1 employer in the global biopharmaceutical industry for the second consecutive year in the journal’s annual Top Employers Survey. Leonard S. Schleifer, M.D., Ph.D., President and CEO of Regeneron, commented, “Regeneron’s tremendous growth and our current expansion plans are undoubtedly thanks to our employees. If we are the best place to work, it is because we have the best employees and a culture where they feel empowered and challenged.” The Full Research Report on Regeneron Pharmaceuticals, Inc. – including full detailed breakdown, analyst ratings and price targets – is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/8ea7_REGN]
Vertex Pharmaceuticals Incorporated Research Report
On October 18, 2013, Vertex Pharmaceuticals Incorporated (Vertex) announced 12-week results from an ongoing Phase 2b study of VX-509, an investigational oral, selective Janus kinase 3 (JAK3) inhibitor, dosed once or twice daily in people with active rheumatoid arthritis (RA) taking methotrexate. According to Vertex, the study met its primary endpoints of both the proportion of people who achieved at least a 20% improvement in signs and symptoms of RA, as measured by the ACR improvement criteria (ACR20), and the change from baseline in Disease Activity Score for 28 joints (DAS28). Robert Kauffman, M.D., Ph.D., Senior Vice President and Chief Medical Officer at Vertex, said, “These results are encouraging and provide further support for the development of VX-509 as a new approach to treating RA and potentially other immune-mediated and inflammatory diseases by selectively targeting JAK3.” Kauffman continued, “In this study, treatment with VX-509 showed good tolerability and resulted in significant improvements in the signs and symptoms of RA across all doses tested. We look forward to the presentation of these data at the ACR annual meeting later this month.” The Full Research Report on Vertex Pharmaceuticals Incorporated – including full detailed breakdown, analyst ratings and price targets – is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/e696_VRTX]
GlaxoSmithKline plc Research Report
On October 23, 2013, GlaxoSmithKline plc (GSK) announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for the once daily inhaled corticosteroid (ICS) treatment, fluticasone furoate (FF), administered using the ELLIPTA dry powder inhaler. GSK reported that the NDA has been submitted for FF monotherapy (100mcg and 200mcg doses) as a once-daily inhaled dry powder maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older. The Company reported that regulatory filings for FF monotherapy are planned in other countries from 2014 onwards. The Full Research Report on GlaxoSmithKline plc – including full detailed breakdown, analyst ratings and price targets – is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/2a35_GSK]
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts’ Corner